Australia's Race Oncology jumps on positive study results for cancer drug

Racura Oncology

06/03/2024 24:42

** Shares of Race Oncology  RAC.AX  rise as much as 10% to
A$0.935, their highest since Nov. 29
    ** Stock posts its biggest intraday gain since Feb. 13
    ** Cancer drugmaker reports positive study results for its
flagship drug, bisantrene, testing it as a treatment for acute
myeloid leukemia (AML), a type of blood cancer
    ** Says bisantrene shows potent activity in a range of
patient-derived primary AML cells and in mouse models of AML
    ** About 386,000 shares change hands, compared with the
30-day average volume of 118,126
    ** Stock up 1.2% YTD as of on last close



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))